Observational Study on the Safety and Effectiveness of Tepezza (teprotumumab) in South Korea

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS1000001085
• Study ID:
  1000001085
• Official title and acronym:
  Observational Study on the Safety and Effectiveness of Tepezza (teprotumumab) in South Korea
• DARWIN EU® study:
  No
• Study countries:
  Korea, Republic of
• Study description:
  This is a multicenter prospective observational study in patients who are prescribed TEPEZZA within the approved indication in a post-marketing setting in South Korea.;
• Study status:
  Planned

Research institutions and networks

Institutions

Amgen

United States

Study timelines

Date when funding contract was signed

Planned:28/02/2026

Actual:26/02/2026

Study start date

Planned:30/09/2026

Data analysis start date

Planned:30/09/2026

Date of interim report, if expected

Planned:30/06/2027

Date of final study report

Planned:30/06/2030

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Study is funded through Amgen, the study sponsor.

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable